soft.report

FDA requires NAION warning on labels of all GLP-1 receptor agonists

The FDA now requires every GLP-1 receptor agonist, from semaglutide to tirzepatide, to carry a labeling warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).

Published Source date: November 9, 2026 soft.report Team

On November 9, 2026, the US Food and Drug Administration (FDA) issued a Drug Safety Communication requiring all manufacturers of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of their labeling.

What was decided

The requirement covers the entire class, not only semaglutide (Ozempic, Rybelsus, Wegovy), which has been at the center of the debate since 2024. It also includes liraglutide, dulaglutide, exenatide, lixisenatide in combination, tirzepatide (a dual GIP/GLP-1 agonist) and orforglipron, approved in 2026. According to the FDA, postmarketing NAION cases have been reported for every currently marketed product in the class.

The evidence behind it

The agency described a totality-of-evidence review rather than a single decisive study:

  • A meta-analysis of 126 randomized controlled trials with 134,253 patients and 288,879 person-years of exposure. It identified 15 probable NAION events: 10 in GLP-1 RA-treated patients and 5 in placebo-treated patients. Incidence was 6.4 per 100,000 person-years with GLP-1 RAs versus 3.8 per 100,000 with comparators.
  • A retrospective cohort in the Sentinel system of adults with type 2 diabetes who started a GLP-1 RA, an SGLT-2 inhibitor or a DPP-4 inhibitor between 2019 and 2024. Crude incidence ranged from 26 to 32 per 100,000 person-years across the three groups. Compared with DPP-4 inhibitors, risk was higher with GLP-1 RAs (HR 1.43; 95% CI 1.02–2.01); compared with SGLT-2 inhibitors, the difference was not significant (HR 1.19; 95% CI 0.91–1.54).
  • Published observational studies with rigorous methods, which consistently showed higher risk in people with type 2 diabetes starting GLP-1 RAs than in those starting DPP-4 or SGLT-2 inhibitors.

The starting point was the study by Hathaway and colleagues, published in JAMA Ophthalmology in July 2024, which linked semaglutide to a higher risk of NAION in a neuro-ophthalmology cohort.

Acknowledged limitations

The FDA itself describes a potential risk, not a confirmed causal relationship. Animal studies did not identify a mechanism, and NAION risk factors (diabetes, hypertension, sleep apnea, kidney disease) overlap with the conditions these drugs treat, making it hard to separate a drug effect from confounding by indication. Absolute differences are small: background NAION incidence in adults older than 50 is 2.3 to 10.2 cases per 100,000 people per year.

In Europe, the EMA's pharmacovigilance committee (PRAC) had already concluded in June 2025 that NAION is a very rare side effect of semaglutide. The US action is broader because it applies to the whole class.

What it means in the clinic

  • The FDA advises that patients immediately report sudden, painless vision loss in one eye, visual field defects or other unilateral visual disturbances.
  • When NAION is suspected, patients should be referred promptly to an ophthalmologist.
  • If NAION is confirmed, clinicians should consider discontinuing the GLP-1 RA unless the benefits clearly outweigh the risk.
  • Patients with prior NAION are at higher risk of recurrence, and an event in one eye raises the risk in the fellow eye.

With growing use of these drugs for diabetes, obesity, cardiovascular disease and sleep apnea, even a modest relative increase may bring more cases to eye clinics. Ophthalmologists are likely to play a more central role in diagnosis and in co-management with endocrinologists and primary care physicians, especially when stopping therapy means giving up important cardiometabolic benefits.

Read the full FDA Drug Safety Communication.

Sources

  1. FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition — U.S. Food and Drug Administration, November 9, 2026
  2. FDA requires NAION warning across the GLP-1 receptor agonist class — Ophthalmology Times, November 9, 2026
  3. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide — JAMA Ophthalmology, July 3, 2024

Informational content, written with AI assistance from the cited sources. It does not replace reading the original study or a medical evaluation.

Ophthalmology reports in your own template

The AI reads the exam, drafts the report in your template, and you review and sign. 15-day free trial, no card.

Discover soft.report